- Lobbying
- Lobbying by Parry, Romani, DeConcini & Symms on behalf of Olympia Pharmacy
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Tami Wahl | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Justice - Dept of (DOJ)
White House Office
Type of Issue
Pharmacy
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
White House Office
Food & Drug Administration (FDA)
Justice - Dept of (DOJ)
Type of Issue
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Food & Drug Administration (FDA)
Justice - Dept of (DOJ)
White House Office
Type of Issue
Pharmacy
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
White House Office
Food & Drug Administration (FDA)
Justice - Dept of (DOJ)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Working to ensure the implementation of the Drug Quality and Security Act (DQSA) (Food, Drug, and Cosmetic Act (503B)) is in alignment with the statutory language. Legislative efforts include working on guidance documents issued by FDA..
Registration
Issue(s) they said they’d lobby about: Legislation and agency guidance documents that impact the operation of pharmacy compounding and access to compounded medications..
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate